← Eichor
Study identifier: NCT05639647 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Condition: Gram-negative Bacterial Infections  ·  Sponsor: Pfizer

PhasePhase 2
Planned participants48
Who can joinAll sexes, 9 Months to 17 Years
Healthy volunteersNo

About this study

The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants. The study is seeking participants who are: * 9 months to less than 18 years of age * Hospitalized * Suspected/known to have a gram-negative infection * Receiving intravenous (iv, given directly into a vein) antibiotics * Being treated for complicated infections of various body parts that includes the abdomen, urinary tract, blood stream, and lungs. * Participants will receive either ATM-AVI or best available therapy (BAT). * Both therapies will be given through a vein. * Participants with complicated abdominal infections will also receive iv Metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - Participants on ATM-AVI treatment who have anaerobic infections will also receive iv MTZ at the study doctor's discretion. * The iv dose of ATM-AVI will be based on the participant's weight and kidney function. * The study doctor will determine the iv dose of BAT. * During the first 2 study days, participants on ATM-AVI therapy will have 5 blood draws in small quantities. * Starting on day 4, the study doctor will decide if participants may be switched to oral therapy. * Participants will receive a maximum of 14 days of ATM-AVI treatment. * After discharge from the hospital, 1 study visit ma…

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (23)

Rady Children's HospitalSan Diego, California, United StatesRecruiting
Weill Cornell Medicine-New York Presbyterian HospitalNew York, New York, United StatesRecruiting
Icahn School of Medicine at Mount SinaiNew York, New York, United StatesRecruiting
Beijing Children's Hospital, Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Guangzhou Women and Children's Medical CenterGuangzhou, Guangdong, ChinaRecruiting
Shanghai Children's Medical CenterShanghai, ChinaRecruiting
University General Hospital of HeraklionHeraklion, Irakleío, GreeceRecruiting
Ippokrateio General Hospital of ThessalonikiThessaloniki, Kentrikí Makedonía, GreeceRecruiting
Semmelweis EgyetemBudapest, HungaryRecruiting
Semmelweis EgyetemBudapest, HungaryRecruiting
RajaRajeswari Medical College and HospitalBangalore, Karnataka, IndiaRecruiting
Medanta Hospital LucknowLucknow, Uttar Pradesh, IndiaRecruiting

+ 11 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05639647